IP Library Granted Patent US 7,303,745
Granted Patent B2
US 7,303,745 · App. 11/144,287 · Granted Dec 4, 2007

Method for preventing or treating the development of respiratory allergies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,303,745
App. No.
11/144,287
Granted
Dec 4, 2007
Kind
B2
Abstract

The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Claims (14)

1. A method for preventing the development of respiratory allergies in a subject, the method comprising prenatally administering and/or postnatally administering to the subject a therapeutically effective amount of LGG prior to allergic sensitization of the subject.

2. The method according to claim 1 , wherein the respiratory allergies are selected from the group consisting of allergic rhinitis, asthma and sinusitis.

3. The method according to claim 1 , wherein the prenatal administration of LGG comprises ingestion of LGG by the pregnant mother of the unborn subject.

4. The method according to claim 1 , wherein the postnatal administration of LGG comprises ingestion of LGG by the subject's mother and breast feeding of the subject by the mother.

5. The method according to claim 1 , wherein the postnatal administration of LGG comprises incorporation of the LGG into an infant formula and consumption of the formula by the subject.

6. The method according to claim 1 , wherein the postnatal administration of LGG continues for at least 3 months.

7. The method according to claim 1 , wherein the postnatal administration of LGG continues for at least 6 months.

8. The method according to claim 1 , wherein the postnatal administration of LGG continues for at least 1 year.

9. The method according to claim 1 , wherein the therapeutically effective amount of LGG is between about 1×10 4 and 1×10 10 cfu/L/kg/day.

10. The method according to claim 1 , wherein the therapeutically effective amount of LGG is between about 1×10 6 and 1×10 9 cfu/L/kg/day.

11. The method according to claim 1 , wherein the therapeutically effective amount of LGG is about 1×10 8 cfu/L/kg/day.

12. The method according to claim 1 , wherein the method additionally comprises prenatally and/or postnatally administering at least one other probiotic.

13. The method according to claim 1 , wherein the method additionally comprises prenatally and/or postnatally administering at least one prebiotic.

14. The method according to claim 1 , wherein the administration of LGG to the subject comprises incorporation of the LGG into an infant formula and consumption of the formula by the subject.

Assignments (6)
MERGER Recorded Mar 9, 2009
From: MJN RESTRUCTURING HOLDCO, INC.
To: MEAD JOHNSON NUTRITION COMPANY
Reel/Frame 022354/0768 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2009
From: BRISTOL-MYERS SQUIBB COMPANY
To: MJN RESTRUCTURING HOLDCO, INC.
Reel/Frame 022248/0663 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2006
From: RENZ, HARALD; BLUEMER, NICOLE; GARN, HOLGER
To: PHILIPPS-UNIVERSITAET MARBURG
Reel/Frame 018452/0875 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2006
From: TRANSMIT GESELLSCHAFT FUR TECHNOLOGIETRANSFER
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 018455/0149 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2006
From: MARBURG, PHILLIPS-UNIVERSITAT
To: TRANSMIT
Reel/Frame 018469/0096 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2006
From: HERZ, UDO
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 018444/0589 →